Long COVID Atlas
Text Theme
Note

EBV reactivation is associated with long COVID, not proven to cause it, and it is absent in many patients. Testing is largely a research tool; the diagram is a schematic.

Mechanism · Virology

EBV reactivation

Most adults carry Epstein-Barr virus, dormant since a past infection. Physical stress can wake it, and several studies link long COVID with signs of recent reactivation. It is a real association, and an honestly limited one: long COVID also happens without it.

Short version: the dormant Epstein-Barr virus can reactivate after COVID and is associated with fatigue and cognitive symptoms, but it is not present in everyone and has not been proven to cause long COVID.

An old virus waking up

Most adults carry Epstein-Barr virus, dormant for life after a past infection. Physical stress can stir it back into activity. Several studies link long COVID with signs of recent EBV reactivation.1

An immune system that will not switch off Persistent viral antigenAutoantibodiesExhausted, misfiring T cells Immune systemkept activated chronic inflammation, tissue effects
In long COVID the immune system often behaves as though the threat never ended. Lingering viral antigen, antibodies that attack the body's own receptors, and T cells stuck in an exhausted, miscoordinated state all keep it switched on. The result is low-grade, chronic inflammation that can injure tissue far from where the virus first landed.

What the studies found

In one early cohort, about a third of long COVID patients showed serological evidence of EBV reactivation, and the associated symptoms were fatigue, insomnia, headache, and confusion. A later cohort tied reactivation markers to fatigue and cognitive symptoms specifically.1, 2

moderate association only

The crucial caveat

Long COVID also occurs in people with no sign of EBV reactivation, so it is not required for the illness. The honest reading is association, possibly a contributor in some, not a proven cause in all.2

causation unproven

Where it fits

Reactivation likely reflects the broader immune dysregulation of long COVID rather than acting alone. There is no proven antiviral treatment for it here, and testing is mainly a research tool for now.

What we don't know

Honest about the edges of the evidence. These are open questions, not settled answers.

  • Whether EBV reactivation contributes to symptoms or simply travels with the illness.
  • Why it appears in some people with long COVID and not others.
  • Whether antiviral treatment against EBV would help, which is unproven.
  • How it interacts with the broader immune disruption.
  • Which other dormant viruses play a similar role.

References

Every reference is free to read in full.

  1. Investigation of long COVID prevalence and EBV reactivation (Gold et al., 2021).
  2. Recent EBV reactivation associated with long COVID symptoms (Peluso et al., 2022).

Associated topics